An Exploratory Study of Functional Outcome in Stimulant Treatment of ADHD in Adults.
Margaret D Weiss, Jeffrey H Newcorn, Pratap Chokka et al.
✦ AI-curated · Sources linked
In 30 seconds
This exploratory analysis examined self-reported functional impairment among adults with ADHD in a forced-dose, double-blind, randomized trial of extended-release methylphenidate (PRC-063) for 4 weeks, followed by a 6-month open-label phase. During the randomized phase, medication produced a statistically significant benefit over placebo in the WFIRS-S work domain; 40% of participants assigned a medication dose met the scale’s criteria for functional improvement. By the end of the open-label phase, two thirds of participants were below symptomatic and functional impairment thresholds. Symptom improvement correlated fairly to moderately with functional improvement, and greater symptom improvement was the strongest predictor of functional gains.
Key findings
- In the 4-week double-blind phase, methylphenidate significantly improved the WFIRS-S work domain versus placebo.
- Forty percent of participants assigned a medication dose met the WFIRS criteria for functional improvement during the double-blind phase.
- At the end of the open-label phase, two thirds of participants were below symptomatic and functional impairment thresholds.
- Symptom and functional changes were fairly to moderately correlated; greater symptom improvement was the strongest predictor of functional improvement.
Why it matters
The findings highlight that symptom response and everyday functioning are related but not interchangeable outcomes in adult ADHD. Some participants improved functionally during treatment, while the study’s conclusion notes that symptom responders may still have residual functional difficulties. Assessing functioning alongside symptoms may therefore help identify needs that symptom scores alone do not capture.
What to keep in mind
The 6-month open-label phase was uncontrolled, so its improvements cannot be attributed to medication with the certainty of the randomized comparison. The authors call for replication using individual dose optimization.